Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
March 23 2021 - 8:30AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, today announced that the
website for Route 79, The Duchenne Scholarship Program, is
officially open and accepting applications. Academic scholarships
of up to $5,000 will be awarded to up to 15 individuals chosen by
an independent committee of Duchenne community members based on an
applicant’s community involvement, personal essay, and
recommendation letter. The Route 79 program is designed to help
students with Duchenne pursue their post-secondary educational
goals.
“We are thrilled to be launching Route 79, The
Duchenne Scholarship Program, for the fourth year. Over the course
of the program, we’ve had the privilege of granting over 50
scholarships to students with Duchenne, as they work to achieve
their unique and varied educational goals. Each year brings new
applicants, along with impressive examples of resilience, ambition,
and commitment to learning. It is our great pleasure to offer this
scholarship to support these students in their pursuit of higher
education. We look forward receiving and evaluating applications
for the next group of Route 79 scholars for the 2021-2022 school
year,” said Diane Berry, Sarepta’s Senior Vice President of Global
Health Policy, Government and Patient Affairs.
The underlying cause of Duchenne is a mutation
or error in the gene coding for dystrophin. Dystrophin is an
essential protein that plays a pivotal role in muscle structure,
function and preservation. The numerical significance of the
scholarship’s name, Route 79, ties to the 79 exons of the
dystrophin gene.
To apply for a scholarship through the Route 79
program, applicants must be accepted to or enrolled in an
accredited college or university or a trade, technical or
vocational school located in the United States and be diagnosed
with Duchenne muscular dystrophy. College seniors or college
graduates accepted to or enrolled in graduate school are also
eligible to apply. Previous recipients of Route 79 scholarships are
eligible to apply for the 2021 Scholarship Program and prior
recognition in the Program will have no bearing on 2021
applications. No consideration will be given to whether an
applicant was previously, is currently, or expects to be in the
future, undergoing treatment with a Sarepta product or
investigational therapy.
Applications will be accepted until May 11, 2021
at 11:59 p.m. PDT. Recipients will be notified prior to August and
awards will be distributed in time for fall 2021 enrollment.
Students may learn more about the program and how to apply by
clicking here.
About Sarepta
TherapeuticsAt Sarepta, we are leading a revolution in
precision genetic medicine and every day is an opportunity to
change the lives of people living with rare disease. The Company
has built an impressive and competitive position in Duchenne
muscular dystrophy (DMD) and in gene therapies for limb-girdle
muscular dystrophies (LGMDs), mucopolysaccharidosis Type IIIA,
Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with
more than 40 programs in various stages of development. The
Company’s programs and research focus span several therapeutic
modalities, including RNA, gene therapy and gene editing. For more
information, please visit www.sarepta.com or follow us on Twitter,
LinkedIn, Instagram and Facebook.
Internet Posting of
InformationWe routinely post information that may be
important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors:Ian Estepan, 617-274-4052,
iestepan@sarepta.com
Media:Tracy Sorrentino, 617-301-8566,
tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2024 to May 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From May 2023 to May 2024